Lundbeck Raises 2026 Forecasts on US Vyepti Demand and Generic Delay
Financial Performance and Outlook
Stronger U.S. Demand and Generic Delay Drive Forecast Increase
May 12 (Reuters) - Danish drugmaker H Lundbeck raised its 2026 sales and earnings growth forecasts on Tuesday, helped by stronger U.S. demand for migraine treatment Vyepti and delayed generic competition for schizophrenia drug Abilify Maintena outside the U.S.
The company's shares rose 4.2% after the announcement.
Updated Financial Guidance
• Lundbeck now expects full-year revenue growth of 7% to 9% at constant exchange rates, up from 5% to 8%, and adjusted EBITDA growth of 8% to 14%, up from 4% to 12%.
First-Quarter Performance Highlights
• First-quarter revenue rose 21% at constant exchange rates to 7.13 billion crowns, though underlying growth was 13% after stripping out a planned one-off inventory build linked to its new partner-market model.
• Lundbeck's first-quarter EBITDA came at 2.63 billion crowns, a rise of 26% from the previous year.
CEO Comments and Pipeline Progress
• "Across our pipeline, assets are advancing well, strengthening our long-term growth potential," CEO Charl van Zyl said in an earnings report.
Additional Information
($1 = 6.3606 Danish crowns)
(Reporting by Jesus Calero and Vera Dvorakova in Gdansk; Editing by Sahal Muhammed)
